在囊性纤维化气道细胞中获得功能的CFTR表达恢复了上皮功能,比野生型或编码子优化的CFTR更好
Maximillian Woodall1, Robert Tarran2, Rhianna Lee2
1Institute for Infection and Immunity, St George's, University of London, Cranmer Terrace, Tooting, London SW17 0RE, UK.
Molecular therapy. Methods & clinical development
|September 13, 2023
概括
针对囊性纤维化 (CF) 的基因疗法显示出有前途. 囊性纤维化转膜调节器 (CFTR) 蛋白质的功能增益变体恢复了肺功能,比CF细胞中的子优化更有效.
科学领域:
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 类 Ia/b 囊性纤维化跨膜调节器 (CFTR) 变体导致严重的囊性纤维化 (CF) 肺病.
- 目前的小分子疗法对这些变体无效.
- 基因CFTR替代提供了潜在的治疗方法,但在体内存在局限性.
研究的目的:
- 调查是否提高CFTR蛋白水平或活性可以改善CF支气管上皮细胞的功能.
- 为了比较子优化,功能的增益 (GOF) 变体和CFTR基因治疗的综合方法的疗效.
主要方法:
- 生成并测试了三种CFTR变异:编码子优化 (hCAI),GOF (K978C) 和组合 (hK978C).
- 在HEK293T细胞中评估CFTR蛋白表达和活性.
- 评估了CF支气管上皮细胞的功能恢复,包括阴离子运输,气道表面液体高度和pH值.
主要成果:
- 在HEK293T细胞中,hCAI和hK978C显示CFTR蛋白质>10倍高,活动比野生型 (WT) 大约4倍.
- 在CF支气管上皮细胞中,K978C CFTR与WT CFTR相比,有效地恢复了上皮功能.
- 由于细胞局部错误,hCAI和hK978C CFTR变异的功能影响有限.
结论:
- 功能获取的CFTR变异可能在CF基因治疗中比编码子优化的方法更有效.
- 细胞局部化对于向CFTR的基因治疗策略的有效性至关重要.
- 这项研究提供了在CF治疗中使用GOF变体的原则证明.
关键词:
在CFTR中,CFTR是最重要的.呼吸道上皮质 呼吸道上皮质气道表面液体是气道的表面液体.离子离子分泌 离子分泌编码器优化编码器优化囊性纤维化症是什么基因治疗的基因疗法唾液 唾液 唾液 是一种更多相关视频
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
10.7K
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
19.3K
相关概念视频
Cystic Fibrosis: Pathogenesis
275
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
275
Cystic Fibrosis: Management
191
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
191
